Management of Malignant Hypercalcemia

Introduction to Malignant Hypercalcemia

The American College of Chest Physicians recommends that malignant hypercalcemia be treated with intravenous rehydration using normal saline solution, followed by intravenous bisphosphonates such as zoledronic acid, which is the treatment of choice for reducing serum calcium levels 1, 2

Malignant hypercalcemia occurs in 10-25% of patients with cancer, being more common in squamous cell lung cancer 3, 4
The main mechanisms include the production of parathyroid hormone-related protein (PTHrP), increased active metabolite of vitamin D (calcitriol), and localized osteolytic hypercalcemia 5
Symptoms depend on the severity and can include mild to moderate symptoms such as polyuria, polydipsia, nausea, confusion, vomiting, abdominal pain, and myalgia, as well as severe symptoms (>14.0 mg/dL) such as altered mental status, bradycardia, and hypotension 5

Measure serum concentrations of intact parathyroid hormone (iPTH) 4
Measure serum concentrations of parathyroid hormone-related protein (PTHrP) 3
Measure serum concentrations of 1,25-dihydroxyvitamin D and 25-hydroxyvitamin D 3
Measure serum concentrations of calcium, albumin, magnesium, and phosphorus 5
PTHrP-mediated hypercalcemia is characterized by suppressed iPTH levels and low or normal calcitriol levels 5

First-line treatment: Rehydration with intravenous crystalloid fluids that do not contain calcium 5, 2
Parenteral hydration with normal saline solution corrects hypovolemia associated with hypercalcemia and promotes calciuresis 1
For mild hypercalcemia, oral hydration may be effective 5

Treatment of choice: Zoledronic acid 4 mg as an intravenous infusion over 15 minutes 1, 2
The 4 mg dose is recommended for initial treatment, reserving the 8 mg dose for recurrent or refractory cases 1
Normalizes calcium levels in approximately 50% of patients by day 4 1, 2
Alternative: Pamidronate 90 mg as an intravenous infusion over 2 hours 1, 2
Normalizes calcium levels in approximately 33% of patients by day 4 1

Loop diuretics (e.g. furosemide) should be administered only after correcting intravascular volume 5, 2

Denosumab: Consider in patients with hypercalcemia refractory to bisphosphonates or with renal insufficiency 1, 6
Reduces serum calcium in 64% of patients with hypercalcemia refractory to bisphosphonates 1
Monitor calcium levels post-treatment due to risk of hypocalcemia 1
Glucocorticoids: Consider in tumors that produce 1,25-dihydroxyvitamin D 1

Renal insufficiency: Denosumab is preferred over bisphosphonates in patients with renal disease 6, 7
Prognosis: Median survival after discovery of malignant hypercalcemia in patients with lung cancer is approximately 1 month 5

Perform baseline dental examination and monitor for jaw osteonecrosis in patients receiving bisphosphonates 6

Zoledronic acid 4 mg given intravenously over ≥ 15 minutes is the preferred first‑line bisphosphonate, showing superior efficacy and longer duration of response compared with pamidronate; calcium normalizes in ≈ 50 % of patients by day 4 versus 33 % with pamidronate. 8
The FDA‑approved regimen for acute hypercalcemia is a single 4‑mg infusion of zoledronic acid; an 8‑mg dose is reserved only for relapsed or refractory disease. 8

For severe hypercalcemia, adding calcitonin 100 IU subcutaneously or intramuscularly to bisphosphonate therapy provides a rapid calcium‑lowering effect within hours, although efficacy is limited by early tachyphylaxis; the combination achieves a faster serum calcium reduction than bisphosphonate alone. 8

Denosumab 120 mg subcutaneously is indicated for bisphosphonate‑refractory hypercalcemia or for patients with significant renal impairment; it reduces serum calcium in ≈ 64 % of such patients within 10 days. The 2023 Endocrine Society guideline recommends denosumab over intravenous bisphosphonates as a conditional recommendation with low‑certainty evidence, especially when bisphosphonate therapy fails. Denosumab is preferred in renal disease because it does not require dose adjustment, although it carries a higher risk of hypocalcemia. 8

Glucocorticoids (e.g., prednisone 20–40 mg/day orally or equivalent methylprednisolone intravenously) are indicated for hypercalcemia caused by excessive intestinal calcium absorption, such as vitamin D intoxication, granulomatous diseases, certain lymphomas, and multiple myeloma. 8